Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celebrex Switches Create Approximately 7% of Scripts For Merck Vioxx

Executive Summary

Switches from Celebrex to Vioxx accounted for approximately 7% of prescriptions for Merck's COX-2 inhibitor during November.

You may also be interested in...

COX-2 inhibitors top 20 mil. scripts

Pfizer/Searle's Celebrex ended 1999 with a total of 16.6 mil. prescriptions following a January 1999 launch, while Merck's Vioxx had 4.6 mil. prescriptions for the year after its May launch, according to IMS Health data

Vioxx Strategy Aims To Switch Patients Up From OTC To Rx Market

Merck is looking to move patients out of the over-the-counter analgesic market to the prescription COX-2 inhibitor Vioxx, Merck Human Health-The Americas President David Anstice said at Merck's annual business briefing Dec. 9 in Whitehouse Station, N.J.

Searle, Merck Promise No More Price Increases Until March 2000

Searle has promised its pharmaceutical buyers that it will not raise prices on any of its products before March 1, 2000.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts